Neuro-Oncology Clinical Trials

With an emphasis on transdisciplinary translational research, the OSUCCC-James facilitates investigator-initiated early phase clinical trials and participates in many cooperative groups.

Protocol No.PITitle
OSU-12161Sergio BergeseA Prospective, Single-Blinded, Randomized Study Of Awake Vs Intubated General Anesthesia In Patients Undergoing Elective Craniotomy For Supratentorial Glioma Resection
OSU-13094Robert CavaliereHSPPC-96 Expanded Access (Compassionate Use) Treatment Protocol for an individual Patient
OSU-07147James ElderOhio Brain Tumor Study (OBTS)
OSU-10130James ElderNIH 1308: The Cancer Genome Atlas Patient Enrollment and Specimen Qualification Criteria Grade II-IV Gliomas
OSU-11122James ElderA Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma and Followed by Treatment with Toca FC, Extended-Release 5-FC
OSU-12105James ElderA Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
RTOG-1205Michael GuiouRandomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
OSU-11108Tim LautenschlaegerBiomarker discovery for toxicity and survival in Radiation Oncology: an integrative molecular-clinical approach
OSU-05094Sean LawlerInvestigating Novel Therapeutic Strategies for Brain Tumor Treatment.
OSU-08118Ehud MendelFunctional Outcome in Patients Following Surgical Decompression and Stabilization for Spinal Metastases: Surgical Impact and Quality of Life
OSU-13224Vinay PuduvalliBTTC11-01: Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients with High-Grade Gliomas
OSU-14037Vinay PuduvalliA Phase 1b, Randomized, Multi-Center, Open-Label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-ã) for Recurrent Glioblastoma or Gliosarcoma
OSU-14066Vinay PuduvalliA Phase 2, multicenter, open-label study of BGJ398 in patients with recurrent resectable or unresectable Glioblastoma
OSU-13089Vinay PuduvalliAn Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
OSU-13072Vinay PuduvalliPhase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab plus Vorinostat in Adults with Recurrent Glioblastoma
OSU-05092James Van BrocklynThe Role Shingosine Kinase in Astrocytic Gliomas.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: